frp1 Antibody

What is FRP1 and why is it significant in biomedical research?

FRP1 appears in scientific literature referring to multiple distinct proteins, which requires careful differentiation for proper antibody selection:

• SFRP1 (Secreted frizzled-related protein 1): A secreted glycoprotein that modulates the Wnt/β-catenin signaling pathway with implications in cancer and neurological diseases. It decreases intracellular beta-catenin levels and has antiproliferative effects on vascular cells. SFRP1 has been characterized as a tumor suppressor in breast and cervical carcinomas .

• ATR (ATR serine/threonine kinase): FRP1 is reported as a synonym for the ATR gene, which encodes a kinase functioning in DNA damage pathways and DNA repair. The human version has a canonical amino acid length of 2644 residues and a protein mass of 301.4 kilodaltons .

For research purposes, confirming which FRP1 protein is under investigation is critical for selecting appropriate antibodies and experimental design.

What are the primary applications for FRP1/SFRP1 antibodies?

Based on available research tools, FRP1/SFRP1 antibodies are validated for multiple applications:

Different antibodies may perform optimally in specific applications, with some antibodies validated for multiple techniques while others may be application-specific .

How should I select the appropriate FRP1/SFRP1 antibody for my research?

Proper antibody selection depends on multiple technical parameters:

• Target specificity: Confirm which FRP1 protein your research focuses on (SFRP1, ATR, or others)

• Species reactivity: Verify compatibility with your experimental system (human, mouse, yeast, bacteria)

• Application validation: Select antibodies documented for your intended application

• Epitope location: Consider antibodies targeting different domains based on research needs

• Antibody format: Choose between conjugated and unconjugated formats based on detection methods

• Clonality: Monoclonal for consistent results or polyclonal for broader epitope recognition

• Validation methods: Prioritize antibodies validated using knockout controls or other rigorous methods

The search results indicate multiple commercial antibodies with distinct specificities. For instance, some antibodies are specific to human SFRP1, while others recognize bacterial, yeast, or Schizosaccharomyces variants, necessitating careful selection based on your experimental system .

What are the critical differences between monoclonal and polyclonal FRP1 antibodies?

The choice between monoclonal and polyclonal antibodies impacts experimental outcomes:

For SFRP1, the antibody format selection should consider whether you need detection of specific isoforms (3 have been identified) or broader recognition across variants .

How can I optimize Western blot protocols for reliable FRP1/SFRP1 detection?

For optimal Western blot results with FRP1/SFRP1 antibodies:

• Sample preparation considerations:

  • For secreted SFRP1: Concentrate culture media or use protein precipitation methods

  • For cellular SFRP1: Use appropriate lysis buffers with protease inhibitors

  • For ATR/FRP1: Nuclear extraction protocols may improve detection

• Protocol optimization:

  • Dilution ranges: Typically 1:200 to 1:2000 (verify manufacturer recommendations)

  • Blocking conditions: BSA or milk-based blockers depending on antibody specifications

  • Expected molecular weights: ~35-40 kDa for SFRP1; ~301.4 kDa for ATR/FRP1

• Cell line selection: Human cell lines with documented FRP1/SFRP1 expression include:

  • HL-60 promyelocytic leukemia cells

  • THP-1 acute monocytic leukemia cells

  • T-84 colorectal carcinoma cells

  • U-87 MG glioblastoma cells

  • MBA-MB-468 breast cancer cells

• Validation controls: Always include:

  • Positive control (cell line with known expression)

  • Negative control (ideally knockout cell line)

  • Blocking peptide controls when available

What methodologies should I use to validate FRP1/SFRP1 antibody specificity?

Rigorous antibody validation is essential for reproducible SFRP1 research:

• Genetic validation approach:

  • Compare antibody signal between SFRP1 knockout and wildtype/parental cell lines

  • This is considered the gold standard for antibody validation

• Peptide competition validation:

  • Pre-incubate antibody with immunizing peptide to block specific binding

  • Should result in signal elimination if antibody is specific

• Multiple antibody validation:

  • Compare results using antibodies targeting different epitopes

  • Consistent results increase confidence in specificity

• Expression system validation:

  • Test in systems with known differential expression levels

  • Correlate antibody signal with mRNA expression data

According to recent research, a standardized experimental protocol comparing readouts in knockout cell lines and isogenic parental controls represents best practice for antibody validation .

How can I use FRP1/SFRP1 antibodies to study Wnt signaling pathway modulation?

SFRP1 functions as a modulator of the Wnt/β-catenin signaling pathway, enabling several research approaches:

• Functional interaction studies:

  • Co-immunoprecipitation with Wnt proteins to detect physical interactions

  • Combine with β-catenin detection to assess pathway activation status

• Mechanistic investigations:

  • Use antibodies in combination with pathway inhibitors/activators

  • Multi-color immunofluorescence to co-localize SFRP1 with Wnt pathway components

• Cancer research applications:

  • Compare SFRP1 expression in normal vs. tumor tissues

  • Correlate with clinicopathological features in malignant gliomas and other cancers

• Angiogenesis research:

  • Investigate SFRP1's antiproliferative effects on vascular cells

  • Study induced angiogenic responses in vivo

How should I approach immunohistochemistry (IHC) optimization for FRP1/SFRP1 detection?

For reliable IHC detection of FRP1/SFRP1:

• Tissue preparation considerations:

  • Fixation: Test both formalin and paraformaldehyde fixation protocols

  • Antigen retrieval: Optimize based on epitope accessibility (heat vs. enzymatic methods)

  • Section thickness: Typically 4-6 μm for optimal antibody penetration

• Controls and validation:

  • Positive control tissues: Human kidney shows SFRP1 expression in convoluted tubule epithelial cell cytoplasm

  • Negative controls: Include primary antibody omission and isotype controls

• Detection systems:

  • Chromogenic: HRP-DAB systems work well for SFRP1 detection

  • Fluorescent: Useful for co-localization studies with other proteins

• Expected localization patterns:

  • Cytoplasmic staining in epithelial cells of kidney convoluted tubules

  • Cytoplasmic localization in MBA-MB-468 human breast cancer cells

How do I troubleshoot inconsistent results with FRP1/SFRP1 antibodies?

When encountering inconsistent results:

• Antibody-related factors:

  • Batch variation: Especially relevant for polyclonal antibodies

  • Storage conditions: Antibody degradation can occur with improper handling

  • Working dilution: Re-optimize for each new lot

• Sample-related factors:

  • Expression levels: SFRP1 may be expressed at low levels requiring sensitive detection

  • Post-translational modifications: May affect epitope recognition

  • Protein degradation: Use fresh samples and appropriate protease inhibitors

• Technical variables:

  • Cross-reactivity: Some antibodies may recognize multiple SFRP family members

  • Non-specific binding: Optimize blocking and washing protocols

  • Detection sensitivity: Consider signal amplification methods for low abundance targets

• Experimental validation:

  • Use orthogonal methods to confirm findings

  • Include appropriate positive and negative controls in each experiment

  • Consider testing multiple antibodies targeting different epitopes

How do I interpret conflicting data between different FRP1/SFRP1 antibodies?

When different antibodies yield conflicting results:

• Epitope differences:

  • Antibodies targeting different domains may perform differently based on protein conformation

  • Some epitopes may be masked by protein-protein interactions

• Isoform specificity:

  • SFRP1 has 3 reported isoforms that may be differentially recognized

  • ATR/FRP1 also has multiple isoforms that could affect detection

• Validation status comparison:

  • Evaluate which antibody has undergone more rigorous validation

  • Prioritize results from antibodies validated with knockout controls

• Resolution strategies:

  • Use genetic approaches (knockout, knockdown) to determine specificity

  • Employ mass spectrometry or other non-antibody methods for verification

  • Test antibodies side-by-side under identical conditions

  • Consider publishing discrepancies to improve scientific reproducibility

How can FRP1/SFRP1 antibodies be utilized in cancer research?

FRP1/SFRP1 antibodies enable multiple cancer research applications:

• Tumor suppressor function:

  • SFRP1 functions as a tumor suppressor in breast and cervical carcinomas

  • Contrast with expression in malignant gliomas suggests context-dependent roles

• Diagnostic applications:

  • IHC staining patterns in different cancer types

  • Correlation with clinical outcomes and treatment response

• Mechanistic studies:

  • Investigation of SFRP1's role in modulating Wnt signaling in tumors

  • Cell cycle regulation effects (delays G1 phase and S phase entry)

• Therapeutic target validation:

  • Monitor SFRP1 expression changes in response to experimental therapies

  • Evaluate pathway modulation in combination treatments

What considerations are important when using FRP1 antibodies in DNA damage response research?

When studying ATR/FRP1 in DNA damage pathways:

• Cellular localization:

  • ATR/FRP1 is primarily localized in the nucleus

  • Consider nuclear extraction protocols for optimal detection

• Experimental design:

  • Combine with DNA damage markers (γH2AX, 53BP1)

  • Study recruitment dynamics to sites of DNA damage

• Cell cycle considerations:

  • ATR/FRP1 activity varies across cell cycle phases

  • Consider cell synchronization in experimental design

• Technical approaches:

  • Phospho-specific antibodies may be required for activation studies

  • Co-immunoprecipitation to study protein-protein interactions in repair complexes

How are FRP1/SFRP1 antibodies being utilized in novel research applications?

Current and emerging research applications include:

• Therapeutic development:

  • Monitoring SFRP1 levels in response to Wnt pathway modulators

  • Evaluating SFRP1 as a biomarker for treatment response

• Regenerative medicine:

  • Studying SFRP1's role in tissue development and regeneration

  • Investigation of kidney development (inhibits tubule formation and bud growth)

• Multiplexed detection systems:

  • Integration with mass cytometry for single-cell protein analysis

  • Combination with other antibodies for pathway mapping

• Structural biology applications:

  • Epitope mapping to understand functional domains

  • Conformation-specific antibodies to study protein dynamics

What methodological advances are improving FRP1/SFRP1 antibody research?

Recent technical advances enhancing FRP1/SFRP1 research include:

• Antibody engineering:

  • Recombinant antibody production for improved consistency

  • Conjugation-ready formats designed for fluorochromes, metal isotopes, and enzymes

• Validation methodologies:

  • Standardized protocols using knockout cell lines

  • Collaborative initiatives addressing antibody reproducibility issues

• Detection technologies:

  • SimpleStep ELISA® for improved sensitivity

  • Multiplex imaging applications for contextual analysis

• Data sharing initiatives:

  • Open publication of antibody characterization results

  • Resources for the scientific community to improve reproducibility

These methodological advances are addressing longstanding challenges in antibody research, potentially leading to more reliable and reproducible FRP1/SFRP1 studies.